Intent to Sole Source - Medical/Scientific Instruments for the Department of Transfusion Medicine, NIH Clinical Center
Special Notice from the National Institutes of Health, for work in Bethesda, Maryland. Due Oct 23, 2026, 12:00 PM (UTC-4), 5 days left.
| Solicitation number | NOI-OLAO-CC-27-000121 |
|---|---|
| Agency | National Institutes of Health |
| Office | National Institutes of Health |
| Notice type | Special Notice |
| Set-aside | None |
| Trade (NAICS) | Analytical Laboratory Instrument Manufacturing (334516) |
| Product or service code | 6640 |
| Place of performance | Bethesda, Maryland |
| Posted | Oct 8, 2026 |
| Response deadline | Oct 23, 2026, 12:00 PM (UTC-4) (5 days left) |
Official notice and attachments
Description
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Fisher Scientific. Acquisition Description: The NIH Clinical Center, Department of Transfusion Medicine (DTM), Infectious Diseases Section requires acquisition of a
- Real-Time PCR System,
- an Automated Nucleic Acid Extractor and
- a microvolume spectrophotometer to support clinical research and the development, optimization, and validation of diagnostic assays for hepatitis viruses and other transfusion-transmitted pathogens.
The required system must support generation of high-quality quantification data from clinical specimens, including viral RNA/DNA and host-derived nucleic acids. The instrument must enable applications such as targeted genome amplification, work with a wider dynamic detection range, support the library prep for viral genome sequencing, and assay development workflows necessary for evaluating test performance and refining diagnostic methods prior to implementation in a clinical testing environment.
The system must meet the following functional and operational requirements: High data accuracy and reproducibility to ensure reliable detection of viral variants and evaluation of assay performance; Low- to moderate-throughput capability appropriate for assay development, pilot studies, and validation activities involving smaller sample sets; Rapid turnaround times to support iterative testing and optimization of clinical assays; Flexible run configurations that allow efficient processing of varying sample volumes without excess capacity; Cost-efficient operation, including the ability to minimize per-run and per-sample costs for pathogen detection; Integrated and streamlined workflows, including nucleic acid extraction, amplification, quantification and data analysis within a platform from the same vendor to reduce complexity and variability; Ease of use and standardized operation, supporting reproducibility and implementation in a clinical laboratory environment; Compatibility with established nucleic acid preparation and amplification methods and existing laboratory workflows.
The flexibility to be using the systems in a CLIA certified environment. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.
All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-27-000121) by 12:00 PM eastern standard time on 10/23/2026 to: [email protected]. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
About the buyer
The National Institutes of Health awarded $5.8 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.